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Nonalcoholic fatty liver disease (NAFLD) defines a spectrum of conditions from simple steatosis to
nonalcoholic steatohepatitis (NASH) and cirrhosis and is regarded as the hepatic manifestation of
the metabolic syndrome. Glucocorticoids can promote steatosis by stimulating lipolysis within
adipose tissue, free fatty acid delivery to liver and hepatic de novo lipogenesis. Glucocorticoids can
be reactivated in liver through 11-hydroxysteroid dehydrogenase type 1 (11-HSD1) enzyme
activity. Inhibitionof11-HSD1hasbeensuggestedasapotential treatment forNAFLD.To test this,
malemicewithglobal (11-HSD1knockout [KO]) and liver-specific (LKO) 11-HSD1 loss of function
were fed theAmerican Lifestyle InducedObesity Syndrome (ALIOS) diet, known to recapitulate the
spectrum of NAFLD, and metabolic and liver phenotypes assessed. Body weight, muscle and adi-
pose tissue masses, and parameters of glucose homeostasis showed that 11-HSD1KO and LKO
mice were not protected from systemic metabolic disease. Evaluation of hepatic histology, triglyc-
eride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were
similar between 11-HSD1KO, LKO, and controlmice. Unexpectedly, histological analysis revealed
significantly increased levelsof immune foci present in liversof11-HSD1KObutnot LKOor control
mice, suggestive of a transition to NASH. This was endorsed by elevated hepatic expression of key
immune cell and inflammatorymarkers. These data indicate that 11-HSD1-deficientmice are not
protected from metabolic disease or hepatosteatosis in the face of a NAFLD-inducing diet. How-
ever, global deficiency of 11-HSD1 did increase markers of hepatic inflammation and suggests a
critical role for 11-HSD1 in restraining the transition to NASH. (Endocrinology 157: 3493–3504,
2016)
Nonalcoholic fatty liver disease (NAFLD) defines aspectrum of diseases ranging from simple steatosis
to nonalcoholic steatohepatitis (NASH), fibrosis, pro-
gressing in rare cases to cirrhosis and hepatocellular
carcinoma (1–3). Around 30% of the United States
adult population has NAFLD with 3%–5% diagnosed
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with NASH (4), leading to increased morbidity and
mortality (5).
Accumulating evidence supports an association be-
tween NAFLD and metabolic syndrome (MetS). Around
75%of obese people haveNAFLD,with insulin resistance
a key mechanistic factor between both conditions (6). As
such, NAFLD can be regarded as the hepatic manifesta-
tion of the MetS, which together increase the risk of de-
veloping cardiovascular disease (6, 7).
Patients affected by glucocorticoid (GC) excess (Cush-
ing syndrome) present with many of the disorders associ-
atedwithMetSandcandevelopNAFLD(8).GCspromote
steatosis through multiple mechanisms including stimu-
lation of lipolysis within adipose tissue resulting in in-
creased free fatty acid (FFA) delivery for utilization in the
liver to produce lipids through enhanced hepatic de novo
lipogenesis (9–11). In most patients with NAFLD and
MetS, circulatingGCconcentrations arenot elevated (12).
However,GCs can be activated in a tissue-specificmanner
through the prereceptor activity of the 11-hydroxys-
teroid dehydrogenase type 1 (11-HSD1) enzyme, with
the site of greatest activity being the liver (13). Thus, he-
patic metabolism affected by GCs is a balance between
circulating delivery and 11-HSD1-mediated intracellu-
lar activation.
Preclinical studies using 11-HSD1 knockout (KO)
and transgenic mice have exemplified the role 11-HSD1
can play in determining hepatic metabolic phenotype.
Global deletion of 11-HSD1 protects against high-fat
diet induced obesity and glucose intolerance, whereas liv-
er-specific 11-HSD1 deletion does not (14–16). 11-
HSD1KO mice are protected from hepatosteatosis in the
face of circulating GC excess and reveal the importance of
adipose tissue in determining hepatic phenotype (14). Fur-
thermore, mice with transgenic overexpression of 11-
HSD1, specifically in adipose and liver, develop hepa-
tosteatosis in the context of a high-fat diet (17, 18).
Data from studies in humans support the idea thatwith
steatosis there is decreased hepatic 11-HSD1-mediated
GC reactivation, possibly due to decrease local GC avail-
ability and preservation of metabolic phenotype (19).
11-HSD1 inhibitors have been the subject of interest re-
garding their use in the treatment of conditions associated
withMetS, with in-excess of 170 compounds having been
developed for this purpose (20–23). Human clinical stud-
ies evaluating NAFLD patients showed that pharmaco-
logical inhibition of 11-HSD1 was able to modestly re-
duce liver fat content over a 12-week treatment period,
althoughwhether thiswas a direct or peripheral effectwas
unclear (24).
Given the important role that 11-HSD1-mediatedGC
metabolism plays in determining systemic and liver met-
abolic phenotype, we hypothesized that global deletion
(11-HSD1KO) and hepatocyte-specific deletion (LKO)
mice would be protected from MetS and hepatosteatosis
when subjected to a potent steatogenic diet. To this end,
we fed 11-HSD1KO mice the American Lifestyle In-
duced Obesity Syndrome (ALIOS) diet which, unlike a
standard high-fat diet, is known to more faithfully reca-
pitulate the spectrum of NAFLD, from steatosis to NASH
(25).
Our data suggest that 11-HSD1 loss of function af-
fords no protection from ALIOS induced obesity, glucose
intolerance, insulin resistance or hepatosteatosis. Unex-
pectedly, we show that in the context of hepatosteatosis,
11-HSD1KO mice have increased inflammation, a pre-
requisite for the progression to NASH, as revealed by an
accumulation of hepatic immune foci and increased ex-
pression of immune and inflammatory markers. These re-
sults suggest a role for 11-HSD1 in restraining hepatic
inflammation in NAFLD.
Materials and Methods
Animal husbandry
Male mice aged 7–8 weeks, with global (11-HSD1KO) and
hepatocyte-specific (LKO) deletions of 11-HSD1 (16, 26);
along with age-matched C57BL/6 control mice (Charles River)
were used. Male mice were used as we did not want to deviate
from the original ALIOS protocol, where advanced hepatoste-
atosis was attained using the feeding protocol described below
(25). Mice were housed 2–3 per cage and maintained at the Bio-
medical Services Unit at the University of Birmingham, and all
procedures conducted in accordancewith theAnimals (Scientific
Procedures) Act 1986; regulated by the United Kingdom Home
Office. Mice were maintained on a 12-hour light, 12-hour dark
cycle at 21°C–22°C and were fed ad libitum, a diet consisting of
45% of calories from fat, of which 11.6% were derived from
transfats (D13022701; Research Diets, Inc). Mice were also
given a high fructose corn syrup equivalent drinking water re-
placement (55% fructose:45% glucose [wt/vol] deionized H2O
at a concentration of 42 g/L). This feeding regimen, referred to
as theALIOSdiet (25),wasmaintained for 16weeks, afterwhich
mice were subjected to exsanguination via cardiac puncture un-
der general anesthetic (isoflurane), followed by cervical disloca-
tion; upon which tissues were excised and weighed. Once
weighed, tissues were dissected then promptly snap-frozen in
liquid nitrogen (LN2) or fixed in 4% formaldehyde (10% for-
malin [vol/vol] PBS).
Metabolic analyses and plasma analytes
After 13 weeks of ALIOS treatment, blood from each mouse
was collected into Microvette EDTA lined hematological tubes,
from lateral tail veins and blood-glucose concentrations mea-
sured using an Accu-Chek monitor. The week after, mice were
fasted overnight and glucose tolerance tests (GTTs) performed;
whereby ip injections of 20% glucose (vol/vol) 0.9% sterile sa-
line solutions at a dose of 2 g/kg were administered. Blood-glu-
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cose concentrations were measured at times (T)0, T15, T30,
T60,T90, andT120minutes after glucose injections. Blood sam-
pleswere also collected at T0 andT30 after glucose injection and
plasma insulin concentrationsmeasuredusing theUltra Sensitive
Mouse Insulin ELISA kit (Crystal Chem).
Insulin tolerance testing (ITT) was performed during week
15 of the study. Mice were fasted for 4 hours and blood-
glucose concentrations measured (T0), followed by the ad-
ministration of insulin (Actrapid) via ip injection at a con-
centration of 0.1 IU/mL (0.1% 100 IU/mL [vol/vol] 0.9%
sterile saline) at a dose of 0.75 IU/kg. Blood-glucose concen-
trations were subsequently measured at 15, 30, 60, 90, and
120 minutes after insulin injections.
PlasmaFFA, triglyceride (TAG), andhigh-density lipoprotein
(HDL)/low-density lipoprotein (LDL) cholesterol concentra-
tions were measured from blood taken via terminal cardiac
bleeds using protocols outlined according to the manufacturer’s
instructions (BioVision).
Hepatic TAG quantification
Hepatic TAG content was ascertained using Biovision’s col-
orimetric assay (Cambridge Bioscience). Briefly, 100 mg of fro-
zen liver tissue was homogenized in 5% Nonidet P-40 before
being heated for 5 minutes at 95°C in a water bath to solubilize
TAGs, samples were left to cool to room temperature and the
process repeated before centrifugation at 13 000 rpm. The re-
sultant supernatants were diluted in distilled H2O and analyzed
on a 96-well Wallac plate reader at 570 nm.
Histological analyses
Freshly excised livers were dissected, processed and embed-
ded in paraffin wax, from which 5-m sections were cut for
analyses viahistological staining.Hematoxylin andeosin (H&E)
staining was used to score hepatosteatosis and inflammation
using the NAFLD activity score (NAS) (27) and trichrome stain-
ing to access fibrosis. All images pertaining to histological anal-
yses were viewed via light microscopy and photomicrographs
taken using a Leica imaging system.
Real-time quantitative PCR
Fragments of frozen liver tissue were homogenized using TRI
Reagent (Sigma-Aldrich) for total RNA isolation. One micro-
gram of total RNA was reversed transcribed to cDNA using
AppliedBiosystemsHighCapacity cDNAReverseTranscription
kit (Life Technologies) following the manufacturer’s instruc-
tions. Reactionmixes consisting of Applied Biosystems TaqMan
Universal PCR Master Mix and primer/probes (assays on de-
mand), along with 1-L cDNA, were made to 20 L with nu-
clease-free water. All primer/probes targeted to genes of interest
were labeled with FAM, whereas the reference gene, invariably
18s, was labeled with VIC; all reactions were singleplex and
performed using Applied Biosystems ABI 7500 sequence detec-
tion system.Gene expressiondatawas graphically representedas
fold changes against controls. Reference genes’ (18s) cycle
threshold (Ct) values from each sample were subtracted fromCt
values of corresponding samples genes of interest for Ct values
(Ct). These values were then averaged and controls averages
taken from those of KOs to give Ct values which were then
incorporated into the equation 2∧ Ct; to normalize cohort
controls values to 1 and KO cohort as fold changes compared
with controls (28).
Statistical analyses
All data are derived from n  13 controls, n  11 11-
HSD1KO, n  9 LKO, and n  9 LKO control male mice with
data presented as the mean  SEM. Statistical analyses were
performed using Mann-Whitney and Student’s t tests and sta-
tistical significance assigned where P .05. Although graphical
representation of RT-qPCR data are presented as fold change
verses controls, statistical analyses were performed using Ct
values.
Results
Effect of ALIOS diet feeding on metabolic
parameters
NAFLD is considered the hepatic manifestation of the
MetS. Thus, we used the ALIOS diet as a means to induce
MetS and fatty liver disease in 11-HSD1KO and control
mice. After 16 weeks of ALIOS diet, controls and 11-
HSD1KO mice showed similar rates of body weight gain
(Figure 1A). Body weight normalized sc fat, gonadal fat,
and perirenal fat pad weights showed no differences, with
evidence for moderately increased accumulation of mes-
enteric fat in 11-HSD1KOs comparedwith controls (P
.01) (Figure 1B). No differences were seen in lean mass
(quadriceps, tibialis anterior, and soleusmuscles) between
11-HSD1KO and control mice (Figure 1C). 11-
HSD1KOmice showed no difference in glucose or insulin
tolerance when compared with control mice (Figure 1, D
and E). Furthermore, neither fed nor fasted state blood-
glucose concentrations were different between 11-
HSD1KO and control mice (Figure 1F). Blood-insulin
concentrations in the fasted state and 30 minutes after
glucose bolus injection showed no differences between
11-HSD1KO and control mice (Figure 1G). We also as-
sessed plasma lipid profiles and showHDL and LDL cho-
lesterol, FFAs and TAGs were no different between 11-
HSD1KO and control mice (Figure 1, H–J). Taken
together, these data suggest that global deletion of 11-
HSD1 does not protect form the metabolic dysregulation
associated with 16 weeks of ALIOS diet feeding, a time
frame validated to cause obesity, insulin resistance, and
dyslipidemia (25).
Hepatic histology and steatosis scoring
ALIOS diet is also an established means to induce the
classical features of hepatosteatosis and fatty liver disease
(25), fromwhich11-HSD1KOmice shouldbeprotected.
However, there were no differences in the macroscopic
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appearance of the liver, or body weight normalized liver
weight between 11-HSD1KO and control mice (Figure
2A). Hepatic TAG content endorsed the liver weight data,
with no differences observed (Figure 2B). Steatosis anal-
ysis, using blind scoring of H&E-stained livers of 11-
HSD1KO and control mice, showed microvesicular and
macrovesicular steatosis in both 11-HSD1KO and con-
trol mice. Although the severity varied across the cohorts,
no differences in overall distribution in lipid accumulation
were observed (Figure 2C). Indeed, qualitative assessment
using NAS showed there was no statistically significant
difference between hepatosteatosis in 11-HSD1KO and
control mice (Figure 2D). Overall, we find that deletion of
11-HSD1 inmice treatedwith the ALIOS diet affords no
protection from hepatic TAG accumulation or classical
histological profile associatedwith hepatosteatosis and an
overall MetS.
Metabolic and hepatic analysis of hepatocyte-
specific 11-HSD1 deletion
We also wished to delineate the contribution of hepa-
tocyte specific-11-HSD1 deletion to the development of
a MetS and fatty liver in ALIOS-fed mice given the high
level of enzyme expression in this cell type and its prom-
inent role in GC-regulated lipid metabolism. To do this,
we subjected hepatocyte-specific KO mice (LKO) to
ALIOS diet for 16weeks. As in 11-HSD1KO, LKOmice
gained weight at a similar rate to controls over the 16
weeks, with no discernible differences in end-point weight
observed (control 34.73 1.47 vs LKO 36.56 0.70 g).
Figure 1. Loss of 11-HSD1 does not protect mice from the adverse metabolic effects from being fed the ALIOS diet for 16 weeks. A, Body
weight. B, Adipose depot weights; 11-HSD1KO mice showed statistically significant differences only in mesenteric depot weights. C, Muscle bed
weights. D, Glucose tolerance. E, Insulin tolerance. F, Fed and fasted blood glucose concentrations. G, Plasma insulin concentrations at T0 and T30
after glucose bolus injection. H, Total, HDL, and LDL plasma cholesterol concentrations. I, Plasma FFA. J, Plasma TAG. SCF, sc fat; GF, gonadal fat;
MF, mesenteric fat; PRF, perirenal fat; TA, tibialis anterior. Mean  SEM; **, P  .01 using Student’s t test; n  13 (controls) and n  11 (11-
HSD1KO).
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No differences in body weight normalized adipose or lean
tissueweights tissueweightswere seen. In terms of glucose
metabolism, area under the curve (AUC) analysis of GTTs
and ITTs again showed no differences between LKO and
control mice (GTT AUC, control 17.23  2.26mM vs
LKO 20.32  2.22mM; ITT AUC, control 7.92 
0.33mM vs LKO 7.35  0.37mM). Furthermore, there
were no differences between normalized liver weight and
hepatic TAG content between control and LKOmice, be-
ing equivalent to the 11-HSD1KO (Figure 3, A and B).
Hepatosteatosis analysis was conducted and showed
equally distributed microvesicular and macrovesicular
Figure 2. Loss of 11-HSD1 does not reduce or delay hepatic lipid accumulation in mice fed the ALIOS diet for 16 weeks. A, Liver to body weight
ratios in controls and 11-HSD1KO. B, Hepatic TAG content in controls and 11-HSD1KO mice. C, H&E-stained sections cut at 5 m of controls
and 11-HSD1KO liver demonstrating levels of macro- and microvesicular steatosis. D, Dot plot representing steatosis in livers of control and 11-
HSD1KO mice was assessed using the NAS grading system. Mean  SEM (A and B), interquartile range (D); n  13 (control) and n  11 (11-
HSD1KO). Scale bars, 200 m.
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steatosis in both LKO and control mice (Figure 3C).
NAS-assessed LKO and control livers showed similar
levels of hepatosteatosis (Figure 3D). These data con-
firmed the overall view that ALIOS diet and its associ-
ated induction ofMetS andNALFD is unaffected by the
11-HSD1 loss of function.
Hepatic inflammation analysis in 11-HSD1KO
mice
It became apparent during the process of blind assess-
ing histological NASs that certain sections displayed
accumulations of hepatic immune foci in the context of
steatosis. To better characterize this, blinded NAS sys-
Figure 3. Mice with hepatocyte-specific deletion of 11-HSD1 have steatosis comparable with global KO mice. A, Liver to body weight ratios in
controls and LKO. B, Hepatic TAG content in controls and LKO mice. C, H&E-stained sections cut at 5 m of control and LKO liver demonstrating
levels of macro- and microvesicular steatosis. D, Dot plot representing steatosis in livers of control and LKO mice, assessed using the NAS grading
system. Mean  SEM (A and B), interquartile range (D); n  9 (control) and n  9 (LKO). Scale bars, 200 m.
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tem quantification of inflammatory and immune foci
was conducted and revealed an average of 80% of fields
of view from 11-HSD1KO livers had 2 or more in-
flammatory foci compared with 30% in controls (P 
.001) (Figure 4, A and B). Importantly, scoring of LKO
immune foci showed no discernible differences with
their controls (Figure 4C). These data suggest that de-
spite no differences in systemic or hepatic metabolic
parameters being observed, 11-HSD1KO livers are
potentially engaged in the early transition to inflamma-
tory disease, and that extrahepatocyte 11-HSD1 ac-
tivity is important to this process.
Markers of inflammation, immune cell infiltration,
and fibrosis in 11-HSD1KO mice
Following the observation of increased immune foci and
early stage inflammatory disease in 11-HSD1KOmice, we
conductedgeneexpressionanalysis formarkersofcytokines,
Figure 4. Loss of 11-HSD1 results in an increased frequency of hepatic inflammatory foci compared with control after 16 weeks of ALIOS diet.
A, H&E-stained sections cut at 5 m show inflammatory foci (arrows) in livers of controls and 11-HSD1KO mice, areas inside boxes highlight
inflammatory foci (magnified an additional 2). B, Dot plot showing % fields of view with 2 or more inflammatory foci; using the Mann-Whitney
test, there was a significant increase in 11-HSD1KO mice compared with controls, which was not seen in livers of LKO mice when compared with
their controls (C). ***, P  .001, interquartile range; n  13 (control), n  11 (11-HSD1KO), n  9 (LKO control), and n  9 (LKO). Foci per field
of view at 200 magnification. Scale bars, 200 m.
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macrophages, lymphocytes and fibrosis to further charac-
terize this finding. The proinflammatory genesTnf andCcl2
were significantly increased in livers of 11-HSD1KO com-
paredwithcontrols (Figure5A).Further to this,macrophage
markers Lgals3, Fsp1, andCd11b, known to be involved in
the earlymodulation ofNASH,were significantly increased,
as were lymphocyte specific markersCd8 andB220 in 11-
HSD1KOcomparedwithcontrols (Figure5,BandC).These
suggest that 11-HSD1 expression in nonhepatocyte cells is
important torestrainingthe immuneresponse toectopic liver
fat accumulation.
Because the pathogenesis of NASH involves the de-
position of collagen and the formation of fibrotic le-
sions as hallmark features of advancing disease, we as-
sessed the expression of fibrosis markers and show that
Col1a1, encoding the major protein component of type
1 collagen, is significantly increased (P  .004) in 11-
HSD1KO but not in control livers. Reelin (Reln) ex-
pressed by hepatic stellate cells can act as a marker of
hepatocyte damage, and was shown not to be altered
(Figure 6A). However, trichrome staining showed no
ectopic collagen deposition evident in either 11-
HSD1KO or control liver, with only collagen of the
tunica externa of blood vessels stained (Figure 6B), sug-
gesting that increased Col1a1 expression was a marker
of the very earliest progression to NASH only seen in
11-HSD1KO mice.
Discussion
Mice deficient in 11-HSD1, or treated with 11-HSD1
inhibitors, resist obesity and a MetS phenotype when fed
conventional high-fat diets (15, 21). Based on observa-
Figure 5. Increased hepatic expression of proinflammatory cytokines and macrophage markers in 11-HSD1KO mice. A, Increased expression of
proinflammatory cytokines Tnf and Ccl2 in the livers of 11-HSD1KO mice. B, Increased expression of macrophage specific markers, Lgals3, Fsp1,
and Cd11b in 11-HSD1KO compared with controls. C, Significant increases were seen in the expression of lymphocyte specific markers Cd8 and
B220. Mean  SEM; *, P  .05; **, P  .01; ***, P  .001 using Student’s t test; n  13 (control) and n  11 (11-HSD1KO).
3500 Larner et al NAFLD in ALIOS-Treated 11-HSD1KO Mice Endocrinology, September 2016, 157(9):3493–3504
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 28 September 2016. at 01:53 For personal use only. No other uses without permission. . All rights reserved.
tions from such models and recent human clinical studies
we postulated that 11-HSD1KOandhepatocyte-specific
KO (LKO) mice would be protected against the develop-
ment of MetS and resist hepatosteatosis when challenged
with the ALIOS diet. After 16 weeks of ALIOS, we show
thatmale 11-HSD1KOand LKOmice are indistinguish-
able from control mice displaying obesity, glucose intol-
erance, dyslipidemia and indeed hepatosteatosis. An in-
crease in mesenteric adipose tissue mass was measured in
11-HSD1KOmice. This runs contrary to that found for
11-HSD1KOmice fed a high-fat diet, in which there was
preferential adipose deposition away from the mesenteric
depot (15). Nonetheless, positive correlations have been
shownbetweenmesenteric fatmass andhepatosteatosis in
human subjects (28–30).
Unlike conventional high-fat diets,ALIOSdiet includes
transfats and fructose, both of which can drive hepatic
lipidmetabolism and accumulation, and have been shown
to exacerbate the development of MetS beyond that
achieved by conventional high-fat diets (25, 31–33). In-
deed ALIOS is also validated to induce a more vigorous
progression from simple steatosis to
NASH, something that high-fat diets
rarely achieve (25, 34).
We had further hypothesized that
KO mice would be protected from
developingovert fatty liver and show
a decrement in lipid accumulation.
However, hepatic lipid accumula-
tion and quantitative NAS analysis
demonstrated no differences be-
tween 11-HSD1KO, LKO, and
their control mice. A number of pre-
clinical animal models have demon-
strated the potential for 11-HSD1
to modulate lipid accumulation and
the NAFLD phenotype. Mice with
transgenic over expression of 11-
HSD1, specifically in adipose and
liver, develop steatosis in the context
of a HFD (17, 18). 11-HSD1KO
and adipose-specific 11-HSD1KO
mice resist hepatosteatosis when
GCs are in circulatory excess,
achieved through the lack of adipose
11-HSD1 limiting lipolysis and he-
patic FFA delivery, whereas LKO
maintained florid steatosis as in
wild-type mice (14, 16). Further-
more, a recent phase 1B clinical trial
using the 11-HSD1 inhibitor
RO5093151 effectively reduced liv-
er-fat content of those treated; however, the tissues me-
diating this effect were not identified (24).
On this basis, we conclude that in the context of the
ALIOS diet, neither global nor hepatocyte-specific 11-
HSD1 loss of function in male mice has any protective
effect against the development of hepatosteatosis.
Simple and benign steatosis is a reversible condition
which precedes more destructive NASH, fibrosis and cir-
rhosis (35). Our unanticipated observations of inflamma-
tory disease only, in 11-HSD1KOmice, implied that we
had collected liver transitioning to the early stage of
NASH. Inflammatory scoring was not a primary end-
point measure in terms of our initial hypothesis regarding
metabolic disease. However, there is accumulating evi-
dence for a prominent role for 11-HSD1 in modulating
local tissue inflammatory responses, regulating early re-
straint of the acute inflammatory process. 11-HSD1 de-
ficiency has been shown to worsen acute inflammation
with greater infiltration of inflammatory cells into target
sites in experimental models of rheumatoid arthritis and
myocardial infarction (36, 37). However, this is not a uni-
Figure 6. Increased expression of fibrosis-associated gene does not correlate with histological
phenotype. A, Significant increases in Col1a1 mRNA, a marker of fibrosis, in 11-HSD1KO mice.
Hepatic stellate cell marker Reelin (Reln), was not increased. B, Assessment of fibrosis using
trichrome stained sections cut at 5 m showed no ectopic collagen in either control or 11-
HSD1KO mice. Mean  SEM; **, P  .01 using Student’s t test; n  13 (control) and n  11
(11-HSD1KO). Scale bars, 100 m.
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versal observation. Reduced inflammation in adipose tis-
sue has been observed in 11-HSD1KO mice, suggesting
tissue-specific inflammatory phenotypes are important
(38).
We endorsed our histological observations by showing
elevated expression of markers of inflammation and im-
mune cell infiltration/activation in livers of 11-HSD1KO
mice when compared with controls. Fibroblast-specific
protein-1 (Fsp1/S100a4), a marker for a subpopulation of
macrophages specific to liver damage was increased yet
F4/80 and Cd68, pan macrophage markers, and Clec4f,
expressed in Kupffer andmigrant liver macrophages were
not. Although no firm conclusions can be drawn, they do
suggest differential regulation of FSP1ve macrophages in
the context of 11-HSD1 and diet-induced hepatic in-
flammation. Importantly, FSP1ve macrophages also ex-
press Cd11b, Ccl2, and Tnf, all of which were also sig-
nificantly increased in 11-HSD1KO mice. Because
several liver resident immune cells types express these
markers, elucidationof the subpopulations involved could
not be ascertained (39–42). In healthy livers, resident im-
mune cells are found in portal tracts and migrate into the
parenchyma upon initiation of an inflammatory response
(43–45). It has been shown that they automodulate their
physiology via intracrine 11-HSD1-mediated reactiva-
tion of GC, regulating processes such as mast cell degran-
ulation, dendritic cell differentiation, and neutrophil and
dendritic cell susceptibility to apoptosis (46–50). This ev-
idence suggests the intrinsic ability of immune cells to au-
toregulate availability of GC is crucial to appropriate im-
mune function.
We postulate that ALIOS induced hepatic inflamma-
tion is initially restrained by extrahepatocyte 11-HSD1
activity in resident hepatic immune cells or/and by periph-
eral extravasated immune cells such as macrophages (51,
52). This is supported by data showing macrophages de-
ficient in 11-HSD1 fail to phagocytose apoptotic neu-
trophils when treated in vitro with 11-HSD1 substrate;
with 11-HSD1KO mice having delayed macrophage
phagocytic competence during induced peritonitis (49).
The enhanced inflammatory phenotype exhibited by 11-
HSD1KO mice also endorses clinical data, whereby ste-
atohepatitis was accompanied with an increase in 11-
HSD1, suggesting a requirement for increasedGC activity
in inflamed livers (19).
Although we show significantly increased hepatic ex-
pression of Col1a1, an early marker of liver collagen de-
position (53), we could not demonstrate histological evi-
dence of fibrosis, and may be due to 16 weeks of ALIOS
being insufficient to evoke fibrotic lesions. ALIOS diet fed
for 12 months has been shown to recapitulate the devel-
opment of NASH, as 80% of animals developed fibrosis
and 60% hepatocellular carcinoma (34).
These data indicate ALIOS as a useful means to exam-
ine the relationship between hepatic 11-HSD1-mediated
GC metabolism, MetS and inflammatory disease. Impor-
tantly,we highlight the need to further explore 11-HSD1
in the context of hepatic inflammation and its role in the
mechanisms that gateway the development ofNASH.Fur-
ther work is required to elucidate the cell types and mech-
anisms critical to resolving hepatic inflammation in the
setting of ALIOS induced NAFLD and MetS. Ultimately,
the clinical application of 11-HSD1 inhibitors as treat-
ments for many of the conditions associated with MetS
may not be advisable when NAFLD is also present.
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